Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients (1997)
    Oxford UK : Blackwell Science Ltd.
    Alimentary pharmacology & therapeutics 11 (1997), S. 0 
    Details
    ISSN: 1365-2036
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Several studies have shown that dual therapy with omeprazole and amoxycillin may cure Helicobacter pylori infection. However, the optimum dose of omeprazole has still to be established.〈section xml:id="abs1-2"〉〈title type="main"〉Methods:An international, randomized, double-blind multicentre trial was conducted in patients with duodenal ulcers to compare the H. pylori cure rates obtained by dual therapy consisting of either omeprazole 20 mg b.d. plus amoxycillin 750 mg b.d. or omeprazole 40 mg b.d. plus amoxycillin 750 mg b.d. for 2 weeks. Dual therapy was followed by omeprazole 20 mg once daily for 2 weeks. Before entering the trial and 4 weeks after cessation of treatment H. pylori infection was assessed by histology and a 13C-urea breath test.〈section xml:id="abs1-3"〉〈title type="main"〉Results:381 patients were randomized into the study, of whom 345 were evaluable for the all-patients-treated analysis of efficacy and 378 were valid for the evaluation of safety. Histology results showed that H. pylori infection was cured in 64 out of 174 patients treated with omeprazole 20 mg b.d. plus amoxycillin and in 102 out of 171 patients treated with omeprazole 40 mg b.d. plus amoxycillin (37% vs. 60%; P 〈  0.001). Both treatment regimens were well tolerated, with adverse events reported by 29 (15.2%) and 35 patients (18.7%), respectively.〈section xml:id="abs1-4"〉〈title type="main"〉Conclusions:This study has shown that dual therapy with amoxycillin 750 mg b.d. and omeprazole 40 mg b.d. is superior to dual therapy with amoxycillin and omeprazole 20 mg b.d. in patients with H. pylori-positive duodenal ulcers. Thus, a true dose–response relationship exists between omeprazole and treatment success. However, a combination of omeprazole with two of amoxycillin, clarithromycin and a nitroimidazole is a preferable alternative for routine clinical use.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1365-2036.1997.00169.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Kinetic properties of human pancreatic carboxylesterase
    Amsterdam : Elsevier
    Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism 754 (1983), S. 142-149 
    Details
    ISSN: 0005-2760
    Keywords: (Human pancreas) ; Carboxylesterase ; Fluorescence ; Kinetics ; Substrate specificity ; Taurocholate
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology , Medicine , Physics
    Type of Medium: Electronic Resource
    URL: http://linkinghub.elsevier.com/retrieve/pii/0005-2760(83)90155-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Therapieprobleme der Hyperlipoproteinämie Typ I (1976)
    Springer
    Journal of molecular medicine 54 (1976), S. 415-422 
    Details
    ISSN: 1432-1440
    Keywords: Hyperlipoproteinemia type I ; Familial hyperlipidemia ; Diet therapy in hyperlipoproteinemias ; Lipoprotein lipase ; Medium chain triglycerides ; Essential fatty acids ; Hyperlipoproteinämie Typ I ; Familiäre Hyperlipidämie ; Diättherapie bei Hyperlipoproteinämie ; Lipoproteinlipase ; Mittelkettige Fettsäuren ; Essentielle Fettsäuren
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Der therapeutische Effekt verschiedener Diäten mit unterschiedlichen Relationen von lang- und mittelkettigem Fett, Kohlenhydraten und Eiweiß wurde bei zwei Geschwistern mit Hyperlipoproteinämie Typ I untersucht. Eine Normalisierung der TG-Werte konnte trotz extrem fettarmer Kost (〈5 g täglich) nicht erreicht werden, da es infolge der relativ kohlenhydratreichen Diät und wahrscheinlich auch wegen der Gabe von MCT zu einer starken Vermehrung der prä-β-Lipoproteine kam. Da es sich um eine lebenslange Therapie handelt, müssen die Risiken einer normal fetthaltigen Kost — vor allem rezidivierende Pankreatitiden durch die exzessiven Chylomikronenspiegel — gegen die einer fettreduzierten und kohlenhydrat-und MCT-reichen Kost — erhöhtes Atheroskleroserisiko durch Hyperpräbetalipoproteinämie — abgewogen werden. Daher erscheinen uns folgende diätetische Richtlinien sinnvoll: 1. Reduktion des langkettigen Fetts auf weniger als 30 g pro Tag, wobei besonders auf eine genügende Linolsäurezufuhr (4–6 g täglich) zu achten ist. 2. Der Kohlenhydratanteil sollte 50 Kalorienprozent nicht überschreiten und vor allem aus Stärke bestehen. 3. Das so entstehende Kaloriendefizit sollte vor allem durch Protein gedeckt werden, was durch spezielle Eiweißanreicherung einzelner Nahrungsmittel möglich ist. 4. Nur bei Schwierigkeiten bei der Einhaltung der eiweißreichen Kost sollte der Einsatz mittelkettigen Fetts erwogen werden.
    Notes: Summary The therapeutic effect of different diets varying in long chain and medium chain triglycerides, carbohydrate, and protein was tested in two siblings with type I hyperlipoproteinemia. Despite administration of an extremely fat reduced diet (〈5 g daily), a normalization of plasma TG could not be obtained because—as a consequence of its high carbohydrate and/or its MCT content—it resulted in a considerable increase in pre-β-lipoproteins. As life long dietary therapy has to be maintained, the risks of a normal fat containing diet (mainly bouts of pancreatitis) and those of a carbohydrate and MCT rich diet (premature atherosclerosis) are to be carefully considered. On the basis of our data we therefore suggest the following dietary regimen: 1. Reduced intake of long chain triglycerides (less than 30 gms per day), but with sufficient amounts of essential fatty acids (4–6 gms linoleate daily). 2. The carbohydrates should not exceed 50% of total calories and ought to consist mainly of starch. 3. The caloric deficit thus generated should be balanced by a high protein intake. This is facilitated by applying a specially protein-enriched food. 4. Medium chain triglycerides may be necessary when adherence to the protein-rich diet turns out to be bad.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01470927
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Determination of apolipoprotein variants by isoelectric focusing in agarose
    Amsterdam : Elsevier
    Analytical Biochemistry 163 (1987), S. 182-187 
    Details
    ISSN: 0003-2697
    Keywords: agarose/urea ; apolipoproteins A-I, A-II, and E ; isoelectric focusing
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1016/0003-2697(87)90110-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Purification of human lysozyme from milk and pancreatic juice
    Amsterdam : Elsevier
    Analytical Biochemistry 139 (1984), S. 224-227 
    Details
    ISSN: 0003-2697
    Keywords: heparin-Sepharose affinity chromatography ; human milk lysozyme ; human pancreatic lysozyme
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1016/0003-2697(84)90409-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Frequency of pancreatitis after endoscopic retrograde cholangiopancreatography with iopromid or iotrolan: a randomized trial (2000)
    Springer
    European radiology 10 (2000), S. 677-680 
    Details
    ISSN: 1432-1084
    Keywords: Key words: Iopromide – Iotrolan – Endoscopic retrograde cholangiopancreatography – Pancreatitis – Contrast media toxicity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. Blood isotone contrast media is considered to be less toxic to vascular and pancreatic duct endothelium than high-osmolar contrast media. In this study we assessed the impact of a low-osmolar contrast agent compared with a blood isotone product on pancreatic damage induced by endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic retrograde sphincterotomy (EST). In a prospective trial 42 consecutive ERCP/EST patients were randomized to receive either iopromid, a low-osmolar non-ionic contrast agent (770 mosmol/kg H2O), or iotrolan, a blood-isotone non-ionic product (320 mosmol/kg H2O). The endoscopies were performed by two experienced endoscopists. Forty patients were included in the study. Blood samples were collected before and 40 min, 2, 4, 6 and 24 h after the endoscopic procedure. Samples were analysed for pancreatic serum enzymes, acute-phase proteins and blood counts. A clinical pain score was investigated. Post-ERCP pancreatitis was diagnosed in 2 patients in the iopromid group and in 5 patients in the iotrolan group. There was no significant difference between groups in the time course of pancreatic serum enzymes, acute-phase proteins or in the pain score. Due to the small number of patients in this study, only stronger differences caused by the two contrast media could have led to statistically significant results. We did not observe statistically significant differences in comparing iotrolan and iopromid concerning ERCP/EST-induced pancreatic damage.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s003300050983
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Serum amyloid A – an indicator of inflammation in ankylosing spondylitis (2000)
    Springer
    Rheumatology international 19 (2000), S. 119-122 
    Details
    ISSN: 1437-160X
    Keywords: Key words Ankylosing spondylitis ; Serum amyloid A ; Disease activity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Biological markers of inflammation are useful for the diagnosis and monitoring of inflammatory rheumatic diseases. The present study tested, whether serum amyloid A (SAA) could be used as a marker of inflammatory disease activity in ankylosing spondylitis (AS). In 72 patients with AS, the two valuable surrogate markers of disease activity, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and an established clinical activity score (Bath Ankylosing Spondylitis Disease Activity Index, BASDAI) were correlated to the serum levels of SAA. It was found that SAA correlates well with ESR, CRP, and BASDAI. Because of its strong correlation, SAA seems to be an additional very useful disease activity marker. When used in diagnosis, and especially in monitoring of inflammation, further studies are required. Another interesting point of view is the described role of plasma SAA as a precursor of Amyloid A (AA) protein in secondary amyloidosis, a known complication in AS. In all probability, high circulating SAA levels are a predisposing indicator of disease activity.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002960050114
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation (1997)
    Springer
    Rheumatology international 17 (1997), S. 45-48 
    Details
    ISSN: 1437-160X
    Keywords: Key words Ileitis terminalis Crohn ; Bone loss ; Sacroiliitis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Patients with Crohn's disease are well known to have local and generalized osteopenia of varying degrees. The aim of this study was to investigate whether the additional involvement of the sacroiliac joint as an extra-intestinal manifestation has an influence on bone turnover in female patients with Crohn's disease. Osteocalcin and other parameters of bone metabolism were measured in 79 female patients with Crohn's disease. Bone mineral density (BMD) was measured using dual energy X-ray absorptiometry (DEXA). Z scores were obtained by comparison with age- and sex-matched normal values. As regards the sacroiliac involvement (n = 26; group 1), we found a significantly lower BMD in the lumbar spine (L4) and in Ward's triangle of the femoral neck compared to controls (P 〈 0.05) and those patients (n = 53; group 2) with pure ileitis terminalis Crohn. Furthermore, the duration of the disease process in patients with Crohn's disease and extra-intestinal involvement was markedly shorter than that of patients in group 2 (P 〈 0.05). In conclusion, osteoporosis in female patients with sacroiliac involvement manifested itself in a more severe way.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/PL00006850
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Polymorphisms of apolipoproteins A-IV and E in a Turkish population living in Germany (1996)
    Springer
    Human genetics 〈Berlin〉 98 (1996), S. 285-290 
    Details
    ISSN: 1432-1203
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine
    Notes: Abstract Human apolipoproteins (apo) E and apo A-IV are polymorphic with significantly different allele frequencies among different ethnic groups. Whereas the variation at the apo E gene locus affects plasma cholesterol levels in all populations studied so far and is associated with longevity in Caucasians, the influence of the common apo A-IV polymorphism on plasma lipoproteins has not been unanimously accepted. We have therefore determined the common apo E and apo A-IV polymorphisms by isoelectric focusing, calculated the respective allele frequencies and studied their effects on plasma lipoproteins in a random sample of 240 nonrelated Turkish subjects (141 males, 99 females) living in Germany and originating from central and eastern Anatolia. When compared with the German population and other Caucasians in Europe a prominence of the apo ɛ3 allele frequency (0.885) was accompanied by a decrease in the frequencies of both the apo ɛ2 allele (0.048) and the apo ɛ4 allele (0.067). Thus, the Turkish population studied here clustered with populations mainly from southern Europe and Japan, which have low ɛ2 and ɛ4 allele frequencies. Also, the frequency of the A-IV-1 allele was higher (0.967) and that of the A-IV-2 allele lower (0.033) in the Turkish subjects studied than in other populations. At an average level of total cholesterol of 194.5 ± 45 mg/dl, no significant influence of the A-IV alleles on plasma lipoproteins was seen. However, apo E and apo B differed significantly between apo E phenotypes, with high levels of apo E and low levels of cholesterol and apo B in carriers of the ɛ2 allele, and vice versa for the ɛ4 allele. The average cholesterol excess for the ɛ2 allele was –7.95 mg/dl, for the ɛ3 allele, –1.34, and for the ɛ4 allele, +14.15 mg/dl. Thus, despite the unusual frequency distribution of the apo E alleles, their effects on plasma lipoproteins are within the range reported for other populations in Europe.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s004390050208
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Wirkung von Bezafibrat bei primären Hyperlipidämien (1982)
    Springer
    Journal of molecular medicine 60 (1982), S. 97-105 
    Details
    ISSN: 1432-1440
    Keywords: Hyperlipidemia ; Lipoproteins ; Bezafibrate ; Lipoprotein-Lipase ; Hyperlipidämie ; Lipoproteine ; Bezafibrat ; Lipoprotein-Lipase
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die Wirkung von Bezafibrat auf Lipid- und Lipoproteinspiegel wurde in einer Langzeitstudie über 40 Wochen bei 27 Patienten mit primären Hyperlipoproteinämien untersucht (12 Patienten mit HLP Typ IV n.F., 7 Patienten mit Typ IIb, 3 Patienten mit Typ IIa, 4 Patienten mit Typ V und 1 Patient mit Typ III). Bezafibrat senkte in diesem Kollektiv das Gesamtcholesterin um 16%, während das HDL-Cholesterin um 28 bzw. 36% anstieg (p〈0,05). Die Serumtriglyzeride fielen um 59% (450 mg Bezafibrat/die) bzw. 66% (600 mg Bezafibrat/die) statistisch signifikant ab (p〈0,05). Bei Hyperlipidämien vom Typ IV, IIb, IIa und V waren Anstiege des HDL-Cholesterins feststellbar. Das LDL-Cholesterin verhielt sich typenspezifisch. Die Aktivität der Lipoproteinlipasen (postheparin) wurde durch Bezafibrat von 10,5±0,7 auf 14,7±0,7 bzw. 15,5±0,8 µmol FFA/ml/Stunde um ca. 30% gesteigert (p〈0,05). Die Nebenwirkungen während Bezafibrat-Behandlung waren gering.
    Notes: Summary The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III). Bezafibrate reduced total cholesterol by 16%, whereas HDL-cholesterol increased by 28% and 36% (p〈0.05). Serumtriglycerides decreased by 59% (450 mg Bezafibrate daily) and by 66% (600 mg Bezafibrate daily) statistically significant (p〈0.05). In hyperlipidemias type IV, IIb, IIa and V increases of HDL-cholesterol could be observed. The course of LDL-cholesterol was different in the various types of hlp. The postheparin-lipoprotein-lipase (PHLA) was activated by treatment with Bezafibrate from 10.5±0.7 to 14.7±0.7 and 15.5±0.8 µmol FFA/ml/h or by 30% (p〈0.05). Only few side-effects during treatment with Bezafibrate could be ascertained.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01716387
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...